Total Payments
$444,214
2024 Payments
$404,398
Companies
18
Transactions
42
Medicare Patients
21,156
Medicare Billing
$5.1M
Payment Breakdown by Category
Research$435,349 (98.0%)
Consulting$7,610 (1.7%)
Food & Beverage$1,174 (0.3%)
Education$80.55 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $435,349 | 3 | 98.0% |
| Consulting Fee | $7,610 | 3 | 1.7% |
| Food and Beverage | $1,174 | 31 | 0.3% |
| Education | $80.55 | 5 | 0.0% |
Payments by Type
Research
$435,349
3 transactions
General
$8,865
39 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $435,349 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,612 | 6 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $2,836 | 2 | $0 (2020) |
| Gilead Sciences, Inc. | $1,622 | 2 | $0 (2022) |
| AIMMUNE THERAPEUTICS, INC. | $189.11 | 2 | $0 (2024) |
| PFIZER INC. | $163.22 | 9 | $0 (2024) |
| Seattle Genetics, Inc. | $117.61 | 2 | $0 (2019) |
| Merck Sharp & Dohme LLC | $70.21 | 2 | $0 (2022) |
| ABBVIE INC. | $58.98 | 3 | $0 (2024) |
| Daiichi Sankyo Inc. | $53.00 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $404,398 | 13 | Eli Lilly and Company ($404,045) |
| 2023 | $159.86 | 5 | Novartis Pharmaceuticals Corporation ($66.57) |
| 2022 | $4,937 | 8 | Novartis Pharmaceuticals Corporation ($3,200) |
| 2021 | $108.10 | 3 | Novartis Pharmaceuticals Corporation ($84.68) |
| 2020 | $2,821 | 3 | AstraZeneca Pharmaceuticals LP ($2,800) |
| 2019 | $9,424 | 6 | Eli Lilly and Company ($9,155) |
| 2018 | $22,149 | 1 | Eli Lilly and Company ($22,149) |
| 2017 | $217.16 | 3 | Novartis Pharmaceuticals Corporation ($160.68) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Genentech, Inc. | Itovebi (Biological) | Food and Beverage | In-kind items and services | $34.69 | General |
| Category: BioOncology | ||||||
| 11/26/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $404,045.00 | Research |
| Study: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | ||||||
| 10/30/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.90 | General |
| Category: Oncology | ||||||
| 09/25/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $43.78 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 09/18/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $6.69 | General |
| Category: ONCOLOGY | ||||||
| 07/03/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Oncology | ||||||
| 06/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $14.11 | General |
| Category: Oncology | ||||||
| 04/30/2024 | PFIZER INC. | INLYTA (Drug), IBRANCE, XTANDI | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: ONCOLOGY | ||||||
| 04/29/2024 | PFIZER INC. | INLYTA (Drug), XTANDI, TALZENNA | Food and Beverage | In-kind items and services | $6.08 | General |
| Category: ONCOLOGY | ||||||
| 04/24/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $145.33 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 12/07/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $39.10 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2023 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $66.57 | General |
| Category: Oncology | ||||||
| 11/14/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Hematology | ||||||
| 08/08/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: ONCOLOGY | ||||||
| 03/31/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2022 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $38.30 | General |
| Category: ONCOLOGY | ||||||
| 09/22/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $13.91 | General |
| Category: Hematology | ||||||
| 09/21/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.80 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2022 | PFIZER INC. | IBRANCE (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: ONCOLOGY | ||||||
| 05/13/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $1,610.00 | General |
| Category: ONC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $435,349 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 62 | 5,284 | 117,405 | $5.1M | $1.7M |
| 2022 | 73 | 5,774 | 121,008 | $4.4M | $1.4M |
| 2021 | 69 | 4,819 | 111,244 | $2.0M | $568,864 |
| 2020 | 65 | 5,279 | 118,831 | $3.9M | $1.4M |
Total Patients
21,156
Total Services
468,488
Medicare Billing
$5.1M
Procedure Codes
269
All Medicare Procedures & Services
269 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 20 | 16,803 | $2.1M | $728,149 | 34.7% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 20 | 7,740 | $719,820 | $293,284 | 40.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 613 | 1,196 | $328,625 | $101,488 | 30.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 34 | 5,340 | $186,900 | $97,532 | 52.2% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 11 | 3,432 | $209,352 | $93,240 | 44.5% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 19 | 2,400 | $208,800 | $85,591 | 41.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 119 | 502 | $150,000 | $46,905 | 31.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 19 | 19,310 | $173,790 | $45,105 | 26.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 26 | 30,000 | $150,000 | $26,272 | 17.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 321 | 361 | $81,225 | $18,965 | 23.3% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 486 | 839 | $51,118 | $17,055 | 33.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 747 | 1,585 | $63,360 | $16,371 | 25.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 782 | 1,957 | $39,120 | $14,868 | 38.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 76 | 89 | $31,150 | $11,603 | 37.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 17 | 82 | $32,800 | $10,860 | 33.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 82 | 184 | $27,600 | $8,211 | 29.8% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 11 | 1,295 | $129,500 | $6,396 | 4.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 28 | 113 | $19,775 | $5,925 | 30.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 95 | 503 | $27,665 | $5,607 | 20.3% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 14 | 323 | $27,455 | $5,563 | 20.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 65 | 223 | $15,833 | $4,712 | 29.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 36 | 93 | $13,950 | $4,313 | 30.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 38 | 75 | $12,375 | $4,034 | 32.6% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 55 | 185 | $9,250 | $3,437 | 37.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 107 | 308 | $18,480 | $3,144 | 17.0% |
About Dr. Margaret Block, M.D
Dr. Margaret Block, M.D is a Hematology & Oncology healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184604118.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Margaret Block, M.D has received a total of $444,214 in payments from pharmaceutical and medical device companies, with $404,398 received in 2024. These payments were reported across 42 transactions from 18 companies. The most common payment nature is "" ($435,349).
As a Medicare-enrolled provider, Block has provided services to 21,156 Medicare beneficiaries, totaling 468,488 services with total Medicare billing of $5.1M. Data is available for 4 years (2020–2023), covering 269 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Omaha, NE
- Active Since 01/17/2006
- Last Updated 07/19/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1184604118
Products in Payments
- KISQALI (Drug) $3,391
- Trodelvy (Drug) $1,610
- ZENPEP (Drug) $189.11
- IBRANCE (Drug) $108.85
- BINIMETINIB (Drug) $100.00
- KEYTRUDA (Biological) $70.21
- Enhertu (Drug) $39.10
- VENCLEXTA (Drug) $37.81
- Itovebi (Biological) $34.69
- INLYTA (Drug) $25.59
- EPKINLY (Drug) $21.17
- BRAFTOVI (Drug) $20.53
- IMBRUVICA (Drug) $16.01
- Vonjo (Drug) $15.94
- PADCEV (Biological) $15.74
- SIR-Spheres Microspheres (Device) $15.22
- OPDUALAG (Drug) $14.11
- Pomalyst (Drug) $13.91
- ENHERTU (Drug) $13.90
- OPDIVO (Biological) $13.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Omaha
James Armitage, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Julie Vose, Md, MD
Hematology & Oncology — Payments: $194,187
Hematology & Oncology $194,187
Peter Silberstein, M.d, M.D
Hematology & Oncology — Payments: $143,878
Hematology & Oncology $143,878
Apar Kishor Ganti, Md, MD
Hematology & Oncology — Payments: $135,871
Hematology & Oncology $135,871
Dr. Krishna Gundabolu, M.d, M.D
Hematology & Oncology — Payments: $75,519
Hematology & Oncology $75,519
Samer Renno, M.d, M.D
Hematology & Oncology — Payments: $66,892
Hematology & Oncology $66,892